Regenerative Medicine and Stem Cells Technologies

Scientists have discovered that cancerous cells in an aggressive type of childhood brain tumour work together to infiltrate the brain, and this finding could ultimately lead to much needed new treatments, according to a new study published in Nature Medicine today.

What if cancer cells could be re-engineered to turn against their own kind? A new study led by researchers at Brigham and Womens Hospital leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer.

Biotech company 10x Genomics, which helps analyze the human biological code to understand and improve health, is one of the best-funded enterprises in Silicon Valley at the intersection of biology and technology.

Gene therapy has gained momentum in the past year, following the federal government’s approval of the first such treatments for inherited retinal diseases and hard-to-treat leukemia.

A team at the University of Manchester have developed a novel stem cell gene therapy approach to treat children with a devastating genetic disease. The approach is currently being developed for clinical trial in patients with the disease.

Innovation has always been the mantra when it comes to biotech stocks. And as such, the biotech sector has been the key driver for new medicines and therapies over the last decade or so.

The Lancet medical journal Friday withdrew two papers authored by disgraced Italian surgeon Paolo Macchiarini, found guilty of misconduct regarding an experimental windpipe graft procedure of which most recipients died.

Platelet-rich plasma (PRP) is believed to provide pain relief and help improve joint function in degenerative joint disease, but a new study has shown that it does not act by promoting stem cell proliferation or enhance the cartilage formation capabilities of mesenchymal stem cells (MSCs).

When skeletal defects are unable to heal on their own, bone tissue engineering (BTE), a developing field in orthopedics can combine materials science, tissue engineering and regenerative medicine to facilitate bone repair.

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019).